Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID-19) pandemic: A case series.

Baraliakos, Xenofon; Tsiami, Styliani; Vijayan, Sooraj; Jung, Haewon; Barkham, Nick

Baraliakos, Xenofon; Tsiami, Styliani; Vijayan, Sooraj; Jung, Haewon; Barkham, Nick.

Baraliakos X; Ruhr-Universität Bochum Rheumazentrum Ruhrgebiet Herne Germany.
Tsiami S; Ruhr-Universität Bochum Rheumazentrum Ruhrgebiet Herne Germany.
Vijayan S; Department of Rheumatology New Cross Hospital Royal Wolverhampton NHS Trust Wolverhampton UK.
Jung H; SUT Academy of Medical Sciences Thiruvananthapuram India.
Barkham N; Celltrion Healthcare Co., Ltd Incheon Korea.

Clin Case Rep ; 10(1): e05205, 2022 Jan.

Article in English | MEDLINE | ID: covidwho-1650504

ABSTRACT

ABSTRACT

The COVID-19 pandemic highlighted the benefits of subcutaneous (SC) administration for healthcare systems. The first SC infliximab, CT-P13 SC, was safe and effective for the treatment of psoriatic arthritis. Observed patient preferences for continuing CT-P13 SC suggest that patients receiving IV infliximab should be offered a switch to CT-P13 SC.

Keywords

COVID19; CTP13 SC; infliximab SC; infliximab subcutaneous; psoriatic arthritis; realworld evidence

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report Language: English Journal: Clin Case Rep Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google